


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A stent comprising one or more compounds of the formula (I)



in which

V is O,

Q is CH_2 ,

Y is phenyl which is substituted by a radical which is selected from the group consisting of 2-phenylethyl, cyclohexyl, 4-chlorophenyl, 4-methoxyphenyl, 4-trifluoromethylphenyl, 4-cyanophenyl, 4-chlorophenoxy, 4-methoxyphenoxy, 4-trifluoromethylphenoxy, 4-cyanophenoxy, 4-methylphenyl,

R^3 is hydrogen or fluorine,

m is an integer from 1 to 2,

W is $-CH_2CH_2-$,

U is -CH₂-,

A is phenyl,

R² is COOH, where R₂ R² is disposed in the 4-position relative to the radical U,


X is (CH₂)₄,

R¹ is COOH,

or a pharmaceutically acceptable salt, hydrate or a mixture of a salt and a hydrate thereof and the pharmaceutically acceptable salts, hydrates and/or mixtures thereof .


2. (Original) The stent as claimed in claim 1, characterized in that the compound of the formula (I) is

4-(((4carboxybutyl)-{2-[(4-phenethylbenzyl)oxy]phenethyl} amino)methyl]benzoic acid hydrochloride



or

4-(((4carboxybutyl)-{2-[(4-phenethylbenzyl)oxy]phenethyl} amino)methyl]benzoic acid



3. (Currently Amended) The stent as claimed in claim 1 ~~or 2~~, which is coated with an additional membrane.
4. (Currently Amended) The stent as claimed in claim 1 ~~any of claims 1 to 3~~, comprising at least one further active ingredient.
5. (Currently Amended) The stent as claimed in claim 1 ~~any of claims 1 to 4~~ for the treatment ~~and/~~ or prophylaxis of restenoses following PTCA.
6. (Currently Amended) The stent as claimed in claim 1 ~~any of claims 1 to 4~~ for the treatment ~~and/~~ or prophylaxis of thromboses following PTCA.
7. (Currently Amended) A method of producing stents, comprising supplying stents with ~~The use of compounds of the formula (I) as defined in claim 1 for or in the production of stents .~~
8. (Currently Amended) ~~A method The use of compounds of the formula (I) as defined in claim 1 for producing stents for the treatment and/or prophylaxis of~~ treating or preventing restenoses and/or thromboses , comprising administering to a patient the stent of claim 1 .
9. (Currently Amended) The method of claim 7 ~~A process for producing stents~~ , characterized

in that stents are coated or filled with one or more compounds of the formula (I) as defined in claim 1.

- 10 (Currently Amended) The method of claim 7 ~~A process for producing stents~~, characterized in that polymeric carrier materials comprising one or more compounds of the formula (I) as defined in claim 1 are shaped to stents.
11. (Currently Amended) A method for treating patients with restenotic arteries , comprising simultaneously using ~~by simultaneous use of~~ one or more compounds of the formula (I) as defined in claim 1, and ~~of~~ a stent.
12. (Currently Amended) The method as claimed in claim 11, characterized in that compounds of the formula (I) as defined in claim 1 are present in or on the stent and are released locally.
13. (Currently Amended) A method for the treatment ~~and/~~ or prophylaxis of restenoses ~~and/~~ or thromboses , comprising ~~by~~ using stents as claimed in claim 1 ~~any of the preceding claims~~ in combination with local ~~and/~~ or systemic administration of other active ingredients suitable for the treatment ~~and/~~ or prophylaxis of restenosis ~~and/~~ or thrombosis.
14. (Currently Amended) The method of claim 13, wherein the administration is ~~A method for the treatment and/or prophylaxis of restenoses and/or thromboses by using stents as claimed in any of the preceding claims in combination with~~ systemic administration ~~of compounds of the formula (I) as defined in claim 1~~.